Adjunct Professor, Molecular and Cell Biology, Baylor College of Medicine
Internal Medicine
Dr. Powel H. Brown, MD
|
|
Give Review
Doctor Powel H. Brown, MD is an expert in the field of Internal Medicine. Powel H. Brown is a published doctor and has 68 publications published. The lastest was: 'AR collaborates with ER in aromatase inhibitor-resistant breast cancer.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- AR collaborates with ERα in aromatase inhibitor-resistant Breast cancer.
- Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative Breast cancer.
- Use of pharmacologic interventions for Breast cancer risk reduction: american society of clinical oncology clinical practice guideline.
- Effect of Zileuton and Celecoxib on Urinary LTE4 and PGE-M Levels in Smokers.
- Hepatic stem cells and transforming growth factor β in hepatocellular Carcinoma.
- Aromatase inhibitors and Breast cancer prevention.
- SLC22A5/OCTN2 expression in Breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE).
- Cancer Preventive Rexinoid Modulates Neutral Lipid Content of Mammary Epithelial Cells through a PPAR?-dependent Mechanism.
- The rearranged during transfection/papillary thyroid Carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive brea...
- A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
- Estrogen Induces c-myc Gene Expression via an Upstream Enhancer Activated by the Estrogen Receptor and the AP-1 Transcription Factor.
- Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer.
- The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.
- Drug development for Cancer chemoprevention: focus on molecular targets.
- Two good choices to prevent Breast cancer: great taste, less filling.
- Inhibition of the p38 kinase suppresses the proliferation of human ER-negative Breast cancer cells.
- A novel look into estrogen receptor-negative Breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelin.
- Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research.
- Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
- Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
- Effect of lapatinib on the development of estrogen receptor-negative mammary Tumors in mice.
- Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.
- Strategies of Hormonal Prevention.
- The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges.
- Combination chemoprevention of HER2/neu-induced Breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
- Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary Tumors.
- The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative Tumors in MMTV-erbB2 mice.
- Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
- Chemoprevention clinical trials: it is time to turn success into progress.
- Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
- Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human Breast cells using oligonucleotide arrays.
- The AP-1 transcription factor regulates postnatal mammary gland development.
- Epidermal growth factor induces insulin receptor substrate-2 in Breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migr...
- Cancer prevention: the importance of accurate risk assessment.
- The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human Breast cells through transcription factor crosstalk: implicati...
- Global gene expression analysis of estrogen receptor transcription factor cross talk in Breast cancer: identification of estrogen-induced/activator protein-1-dependent...
- Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary Tumors.
- Novel agents for the prevention of Breast cancer: targeting transcription factors and signal transduction pathways.
- The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary Tumors in transgenic mice.
- Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
- Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 Breast cancer cells.
- Cancer epidemiology, biomarkers & prevention and Cancer prevention research: two journals, a common goal.
- Cancer epidemiology, biomarkers & prevention, and Cancer prevention research: two journals, a common goal.
- Preventive therapy for Breast cancer: a consensus statement.
- Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary Cancer models.
- Prevention of ER-negative Breast cancer.
- The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated Carcinoma cell differentiation and proliferation.
- Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive Breast cancer.
- Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitoti...
- Advances in Breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).
- Identification of conserved gene expression features between murine mammary carcinoma models and human Breast tumors.
- Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of Breast cancer growth.
- Transgenic mouse models for the prevention of Breast cancer.
- Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha.
- cFos is critical for MCF-7 Breast cancer cell growth.
- Prevention of Breast cancer: current state of the science and future opportunities.
- Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models.
- Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ Breast cancer.
- Tumor-suppressor activity of RRIG1 in Breast cancer.
- Translational approaches for the prevention of estrogen receptor-negative Breast cancer.
- Chemoprevention of hormone receptor-negative Breast cancer: new approaches needed.
- Stimulatory effect of genistein and apigenin on the growth of Breast cancer cells correlates with their ability to activate ER alpha.
- Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits Breast cancer growth.
- AP-1 blockade in Breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
- Estrogen receptor DNA binding is not required for estrogen-induced Breast cell growth.
- Receptor-selective retinoids inhibit the growth of normal and malignant Breast cells by inducing G1 cell cycle blockade.
Schools
New York University
Duke University
Duke University Med Center
NciNih
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Drug Facts
| NPI NUMBER | 1356421788 | |
| NPPES Provider LastName | BROWN | |
| NPPES Provider FirstName | POWEL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 129.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356421788 |
| Last Name Of The Provider | BROWN |
| First Name Of The Provider | POWEL |
| View All |
Similar Doctors
|
|
Dr. Ayanna N. Jones, MD |
|
|
Dr. Manjulatha Nukala, MD |
|
Dr. Dara R. Wang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ricardo V. Bellera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Fromm Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rammurti T. Kamble, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rhoda Y. Chang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald R. Galfione, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John P. Levins, MD
This Doctor is OpenDoctor Recommended.
|